Ardelyx Stock Price, News & Analysis (NASDAQ:ARDX)

$5.50 -0.10 (-1.79 %)
(As of 02/23/2018 03:48 PM ET)
Previous Close$5.50
Today's Range$5.35 - $5.75
52-Week Range$4.05 - $15.40
Volume360,800 shs
Average Volume306,948 shs
Market Capitalization$266.20 million
P/E Ratio-2.61
Dividend YieldN/A
Beta0.44

About Ardelyx (NASDAQ:ARDX)

Ardelyx logoArdelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.

Receive ARDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARDX
CUSIPN/A
Phone510-745-1700

Debt

Debt-to-Equity RatioN/A
Current Ratio8.50%
Quick Ratio8.50%

Price-To-Earnings

Trailing P/E Ratio-2.61209590988381
Forward P/E Ratio-2.74
P/E GrowthN/A

Sales & Book Value

Annual Sales$24.03 million
Price / Sales10.88
Cash FlowN/A
Price / CashN/A
Book Value$4.08 per share
Price / Book1.35

Profitability

Trailing EPS($2.23)
Net Income$-112,380,000.00
Net MarginsN/A
Return on Equity-66.87%
Return on Assets-59.72%

Miscellaneous

Employees93
Outstanding Shares47,530,000

Ardelyx (NASDAQ:ARDX) Frequently Asked Questions

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

How were Ardelyx's earnings last quarter?

Ardelyx Inc (NASDAQ:ARDX) issued its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.10. During the same quarter in the prior year, the firm earned ($0.65) EPS. View Ardelyx's Earnings History.

Where is Ardelyx's stock going? Where will Ardelyx's stock price be in 2018?

6 Wall Street analysts have issued 1 year price targets for Ardelyx's stock. Their predictions range from $12.00 to $17.00. On average, they expect Ardelyx's share price to reach $13.67 in the next twelve months. View Analyst Ratings for Ardelyx.

What are Wall Street analysts saying about Ardelyx stock?

Here are some recent quotes from research analysts about Ardelyx stock:

  • 1. According to Zacks Investment Research, "Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California. " (2/2/2018)
  • 2. Cantor Fitzgerald analysts commented, "T3MPO-1 is a Relevant Trial. The results of the trial, disclosed May 12, yielded a statistically significant outcome in the primary endpoint and in seven of eight secondary endpoints. However, the results showed a less-than-expected benefit, in our view, with 27% of tenapanor-treated patients achieving the primary endpoint versus 18.7% for placebo (p=0.02), although the responder rate was less than was observed in the Phase IIb study." (5/31/2017)

Who are some of Ardelyx's key competitors?

Who are Ardelyx's key executives?

Ardelyx's management team includes the folowing people:

  • David M. Mott, Independent Chairman of the Board (Age 51)
  • Michael G. Raab, President, Chief Executive Officer, Director (Age 52)
  • Mark E. Kaufmann, Chief Financial Officer, Principal Accounting Officer (Age 49)
  • Reginal Seeto, Chief Operating Officer, Executive Vice President (Age 45)
  • Jeremy S. Caldwell Ph.D., Executive Vice President, Chief Scientific Officer (Age 48)
  • Elizabeth Grammer Esq., Senior Vice President, General Counsel (Age 53)
  • David P. Rosenbaum Ph.D., Chief Development Officer (Age 56)
  • Robert B. Bazemore Jr., Independent Director (Age 49)
  • William C. Bertrand Jr. Esq., Independent Director (Age 52)
  • Annalisa M. Jenkins, Independent Director (Age 52)

Who owns Ardelyx stock?

Ardelyx's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.35%), Rock Springs Capital Management LP (4.79%), Opaleye Management Inc. (1.89%), Crestline Management LP (0.97%), Teachers Advisors LLC (0.71%) and Candriam Luxembourg S.C.A. (0.63%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Gordon Ringold, Jeffrey W Jacobs, Jeremy S Caldwell, Nea 15 Gp, Llc and Reginald Seeto. View Institutional Ownership Trends for Ardelyx.

Who sold Ardelyx stock? Who is selling Ardelyx stock?

Ardelyx's stock was sold by a variety of institutional investors in the last quarter, including Kennedy Capital Management Inc., BlackRock Inc., Citadel Advisors LLC and Alliancebernstein L.P.. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Forest Baskett, Jeremy S Caldwell and Reginald Seeto. View Insider Buying and Selling for Ardelyx.

Who bought Ardelyx stock? Who is buying Ardelyx stock?

Ardelyx's stock was bought by a variety of institutional investors in the last quarter, including Crestline Management LP, Candriam Luxembourg S.C.A., Rock Springs Capital Management LP, Opaleye Management Inc., Renaissance Technologies LLC, Millennium Management LLC, Deutsche Bank AG and Virtus Fund Advisers LLC. Company insiders that have bought Ardelyx stock in the last two years include Gordon Ringold and Nea 15 Gp, Llc. View Insider Buying and Selling for Ardelyx.

How do I buy Ardelyx stock?

Shares of Ardelyx can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ardelyx's stock price today?

One share of Ardelyx stock can currently be purchased for approximately $5.50.

How big of a company is Ardelyx?

Ardelyx has a market capitalization of $266.20 million and generates $24.03 million in revenue each year. The biopharmaceutical company earns $-112,380,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Ardelyx employs 93 workers across the globe.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]


MarketBeat Community Rating for Ardelyx (ARDX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  214 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  342
MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ardelyx (NASDAQ:ARDX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.67$13.67$16.00$15.60
Price Target Upside: 140.61% upside91.14% upside153.97% upside231.91% upside

Ardelyx (NASDAQ:ARDX) Consensus Price Target History

Price Target History for Ardelyx (NASDAQ:ARDX)

Ardelyx (NASDAQ:ARDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2018Cantor FitzgeraldSet Price TargetBuy$12.00HighView Rating Details
11/29/2017CitigroupBoost Price TargetBuy -> Buy$16.00 -> $17.00LowView Rating Details
11/28/2017WedbushReiterated RatingOutperform$13.00 -> $12.00LowView Rating Details
11/22/2017Ladenburg Thalmann Financial ServicesLower Price TargetBuy -> Buy$19.00 -> $16.00N/AView Rating Details
10/17/2017Leerink SwannReiterated RatingOutperform$13.00N/AView Rating Details
5/23/2017BTIG ResearchLower Price TargetBuy$18.00 -> $12.00HighView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$26.00 -> $21.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$26.00 -> $21.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Ardelyx (NASDAQ:ARDX) Earnings History and Estimates Chart

Earnings by Quarter for Ardelyx (NASDAQ:ARDX)

Ardelyx (NASDAQ ARDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.54)($0.44)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.63)($0.54)ViewListenView Earnings Details
5/5/2017Q1 2017($0.65)($0.59)ViewN/AView Earnings Details
2/17/2017Q4 2016($0.66)($0.66)ViewN/AView Earnings Details
11/7/2016Q316($0.74)($0.65)ViewListenView Earnings Details
8/8/2016Q216($0.75)($0.83)ViewN/AView Earnings Details
5/9/2016Q116($0.66)($0.70)ViewN/AView Earnings Details
3/4/2016Q4($0.82)($0.65)ViewN/AView Earnings Details
11/12/2015Q315($0.48)($0.70)ViewListenView Earnings Details
8/12/2015Q215$0.09$0.42$25.87 million$17.70 millionViewListenView Earnings Details
5/12/2015Q1($0.02)($0.19)$9.65 million$5.88 millionViewN/AView Earnings Details
2/25/2015Q4 2014($0.06)($0.21)$8.15 million$6.34 millionViewListenView Earnings Details
8/7/2014Q2 2014$1.83$0.44$8.10 million$9.14 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Ardelyx (NASDAQ:ARDX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.88)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.20)($0.20)($0.20)
Q2 20181($0.21)($0.21)($0.21)
Q3 20181($0.23)($0.23)($0.23)
Q4 20181($0.24)($0.24)($0.24)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Ardelyx (NASDAQ:ARDX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Ardelyx (NASDAQ ARDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.47%
Institutional Ownership Percentage: 77.52%
Insider Trades by Quarter for Ardelyx (NASDAQ:ARDX)
Institutional Ownership by Quarter for Ardelyx (NASDAQ:ARDX)

Ardelyx (NASDAQ ARDX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/24/2017Reginald SeetoCOOSell10,008$5.20$52,041.60View SEC Filing  
8/30/2017Forest BaskettMajor ShareholderSell485$4.95$2,400.75View SEC Filing  
4/18/2017David P. RosenbaumInsiderSell2,051$11.98$24,570.98View SEC Filing  
3/3/2017Jeremy S. CaldwellEVPSell1,026$14.14$14,507.64View SEC Filing  
12/16/2016David P RosenbaumSVPSell900$14.48$13,032.0022,144View SEC Filing  
10/11/2016Jeffrey W. JacobsSVPSell6,000$15.00$90,000.00View SEC Filing  
9/23/2016Elizabeth A GrammerSVPSell5,000$12.00$60,000.001,440View SEC Filing  
9/19/2016Elizabeth A. GrammerSVPSell6,859$11.21$76,889.39View SEC Filing  
7/18/2016Nea 15 Gp, LlcMajor ShareholderBuy1,527,301$8.73$13,333,337.73View SEC Filing  
3/21/2016Gordon RingoldDirectorBuy15,000$7.77$116,550.00View SEC Filing  
1/13/2016Nea 15 Gp, LlcMajor ShareholderBuy1,000,000$10.00$10,000,000.00View SEC Filing  
11/27/2015Jeffrey W. JacobsSVPSell2,000$20.00$40,000.0047,420View SEC Filing  
10/8/2015Jeffrey W. JacobsSVPSell2,000$19.88$39,760.0047,420View SEC Filing  
9/22/2015David P. RosenbaumSVPSell1,400$22.05$30,870.0025,880View SEC Filing  
9/15/2015David P RosenbaumSVPSell2,540$22.01$55,905.4025,880View SEC Filing  
9/10/2015Jeffrey W. JacobsSVPSell2,000$20.59$41,180.0047,420View SEC Filing  
9/8/2015Michael RaabCEOSell9,785$20.29$198,537.651,518View SEC Filing  
9/3/2015David P RosenbaumSVPSell2,537$18.78$47,644.8625,880View SEC Filing  
7/22/2015Elizabeth A GrammerVPSell2,500$18.00$45,000.00View SEC Filing  
7/15/2015Elizabeth A GrammerVPSell10,000$17.12$171,200.00View SEC Filing  
6/10/2015Gordon RingoldDirectorBuy10,000$15.19$151,900.00View SEC Filing  
6/5/2015Enterprise Associates 12 NewMajor ShareholderBuy1,869,159$10.70$20,000,001.30View SEC Filing  
6/5/2015Peter G SchultzDirectorBuy46,729$10.70$500,000.30View SEC Filing  
5/4/2015Mark KaufmannCFOSell9,083$10.81$98,187.23View SEC Filing  
4/6/2015Mark KaufmannCFOSell7,681$12.80$98,316.80View SEC Filing  
3/2/2015Elizabeth A GrammerVPSell1,737$15.81$27,461.97View SEC Filing  
2/4/2015Jeffrey W JacobsVPSell8,888$16.28$144,696.64View SEC Filing  
1/8/2015Ventures Vii Lp CmeaMajor ShareholderSell300,000$24.25$7,275,000.00View SEC Filing  
12/26/2014Scott D SandellMajor ShareholderSell1,972$21.28$41,964.16View SEC Filing  
6/24/2014Ventures Vii Lp CmeaMajor ShareholderBuy316,826$14.00$4,435,564.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ardelyx (NASDAQ ARDX) News Headlines

Source:
DateHeadline
Ardelyx (ARDX) Downgraded by BidaskClub to "Sell"Ardelyx (ARDX) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - February 18 at 3:32 PM
Cantor Fitzgerald Reiterates "$12.00" Price Target for Ardelyx (ARDX)Cantor Fitzgerald Reiterates "$12.00" Price Target for Ardelyx (ARDX)
www.americanbankingnews.com - February 12 at 1:32 PM
Ardelyx (ARDX) Reports Departure its Chief Scientific Officer - StreetInsider.comArdelyx (ARDX) Reports Departure its Chief Scientific Officer - StreetInsider.com
www.streetinsider.com - February 12 at 6:37 AM
Ardelyx Announces Departure of Chief Scientific OfficerArdelyx Announces Departure of Chief Scientific Officer
finance.yahoo.com - February 12 at 6:37 AM
Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare ConferenceArdelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 3:24 PM
Ardelyx (ARDX) Downgraded by BidaskClubArdelyx (ARDX) Downgraded by BidaskClub
www.americanbankingnews.com - February 3 at 8:46 PM
Ardelyx (ARDX) Cut to Hold at Zacks Investment ResearchArdelyx (ARDX) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - February 2 at 5:36 PM
Ardelyx (ARDX) Stock Rating Upgraded by Zacks Investment ResearchArdelyx (ARDX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 30 at 5:56 PM
Ardelyx Inc (ARDX) Given Average Recommendation of "Buy" by BrokeragesArdelyx Inc (ARDX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 30 at 8:18 AM
Ardelyx (ARDX) Stock Rating Upgraded by BidaskClubArdelyx (ARDX) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - January 27 at 4:28 PM
Ardelyx (ARDX) Downgraded by Zacks Investment Research to HoldArdelyx (ARDX) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - January 23 at 6:44 PM
Ardelyx (ARDX) Stock Rating Lowered by BidaskClubArdelyx (ARDX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - January 21 at 4:58 PM
Stock Review for Biotechs Investors -- Ardelyx, Verastem, and ... - PR Newswire (press release)Stock Review for Biotech's Investors -- Ardelyx, Verastem, and ... - PR Newswire (press release)
www.prnewswire.com - January 12 at 11:08 AM
BRIEF-Ardelyx Says Co Had About $134 Million In CashBRIEF-Ardelyx Says Co Had About $134 Million In Cash
www.reuters.com - January 8 at 8:56 AM
Ardelyx Inc (ARDX) Receives Consensus Rating of "Buy" from BrokeragesArdelyx Inc (ARDX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 5 at 8:28 AM
Can The Uptrend Continue for Ardelyx (ARDX)?Can The Uptrend Continue for Ardelyx (ARDX)?
finance.yahoo.com - January 4 at 11:03 AM
Ardelyx (ARDX) Given a $12.00 Price Target by Cantor Fitzgerald AnalystsArdelyx (ARDX) Given a $12.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - January 3 at 7:10 PM
Ardelyx (ARDX) Reports Positive Results of T3MPO-3 Safety Extension Study of Tenapanor for IBS-C; Plans NDA ... - StreetInsider.comArdelyx (ARDX) Reports Positive Results of T3MPO-3 Safety Extension Study of Tenapanor for IBS-C; Plans NDA ... - StreetInsider.com
www.streetinsider.com - January 3 at 3:50 PM
BRIEF-Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-CBRIEF-Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-C
www.reuters.com - January 3 at 10:38 AM
Ardelyx Inc (NASDAQ:ARDX): Is It A Good Long Term Opportunity?Ardelyx Inc (NASDAQ:ARDX): Is It A Good Long Term Opportunity?
finance.yahoo.com - January 3 at 10:38 AM
January Growth Stock OpportunitiesJanuary Growth Stock Opportunities
finance.yahoo.com - January 1 at 3:50 PM
Why Ardelyx (ARDX) Could Beat Earnings Estimates Again - NasdaqWhy Ardelyx (ARDX) Could Beat Earnings Estimates Again - Nasdaq
www.nasdaq.com - December 27 at 11:49 AM
Reviewing KemPharm (KMPH) and Ardelyx (ARDX)Reviewing KemPharm (KMPH) and Ardelyx (ARDX)
www.americanbankingnews.com - December 26 at 11:54 PM
Why Ardelyx (ARDX) Could Beat Earnings Estimates AgainWhy Ardelyx (ARDX) Could Beat Earnings Estimates Again
finance.yahoo.com - December 26 at 12:19 PM
Ardelyx (ARDX) Enters License Agreement with Shanghai Fosun for Tenapanor in China - StreetInsider.comArdelyx (ARDX) Enters License Agreement with Shanghai Fosun for Tenapanor in China - StreetInsider.com
www.streetinsider.com - December 12 at 11:50 AM
BRIEF-Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co for Tenapanor in ChinaBRIEF-Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co for Tenapanor in China
www.reuters.com - December 11 at 11:51 AM
Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in ChinaArdelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China
finance.yahoo.com - December 11 at 11:51 AM
Ardelyx, Inc. (ARDX) Given Consensus Recommendation of "Buy" by AnalystsArdelyx, Inc. (ARDX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 11 at 5:56 AM
Ardelyx, Inc. Expected to Earn FY2017 Earnings of ($1.88) Per Share (ARDX)Ardelyx, Inc. Expected to Earn FY2017 Earnings of ($1.88) Per Share (ARDX)
www.americanbankingnews.com - December 1 at 11:07 AM
Ardelyx (ARDX): PT To $17 After Partnering with KHK in Japan - Citi - StreetInsider.comArdelyx (ARDX): PT To $17 After Partnering with KHK in Japan - Citi - StreetInsider.com
www.streetinsider.com - November 30 at 3:48 PM
Ardelyx (ARDX) Reports Licensing Agreement with Kyowa Hakko Kirin for Tenapanor for Cardiorenal Diseases in Japan - StreetInsider.comArdelyx (ARDX) Reports Licensing Agreement with Kyowa Hakko Kirin for Tenapanor for Cardiorenal Diseases in Japan - StreetInsider.com
www.streetinsider.com - November 29 at 3:50 PM
Citigroup Raises Ardelyx (ARDX) Price Target to $17.00Citigroup Raises Ardelyx (ARDX) Price Target to $17.00
www.americanbankingnews.com - November 29 at 11:32 AM
Ardelyxs (ARDX) Outperform Rating Reiterated at WedbushArdelyx's (ARDX) Outperform Rating Reiterated at Wedbush
www.americanbankingnews.com - November 28 at 4:26 PM
Ardelyx (ARDX) PT Set at $12.00 by Cantor FitzgeraldArdelyx (ARDX) PT Set at $12.00 by Cantor Fitzgerald
www.americanbankingnews.com - November 28 at 9:12 AM
Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan - PR Newswire (press release)Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan - PR Newswire (press release)
www.prnewswire.com - November 28 at 5:10 AM
Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in JapanArdelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan
finance.yahoo.com - November 28 at 5:10 AM
Brokers Issue Forecasts for Ardelyx, Inc.s Q1 2018 Earnings (ARDX)Brokers Issue Forecasts for Ardelyx, Inc.'s Q1 2018 Earnings (ARDX)
www.americanbankingnews.com - November 27 at 5:56 AM
 Analysts Expect Ardelyx, Inc. (ARDX) to Announce -$0.45 EPS Analysts Expect Ardelyx, Inc. (ARDX) to Announce -$0.45 EPS
www.americanbankingnews.com - November 24 at 11:16 AM
Ardelyx, Inc (ARDX) PT Lowered to $16 at Citi; RDX7675 in Hyperkalemia Discontinued on Safety - StreetInsider.comArdelyx, Inc (ARDX) PT Lowered to $16 at Citi; 'RDX7675 in Hyperkalemia Discontinued on Safety' - StreetInsider.com
www.streetinsider.com - November 22 at 4:37 PM
Ardelyx, Inc. (ARDX) Stock Rating Reaffirmed by Cantor FitzgeraldArdelyx, Inc. (ARDX) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - November 22 at 1:44 PM
Ardelyx, Inc. (ARDX) Price Target Cut to $16.00 by Analysts at Ladenburg Thalmann Financial ServicesArdelyx, Inc. (ARDX) Price Target Cut to $16.00 by Analysts at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - November 22 at 10:50 AM
First 2-drug HIV Regimen Gets FDA Nod, Starpharma Shines, ARDX Drops RDX7675First 2-drug HIV Regimen Gets FDA Nod, Starpharma Shines, ARDX Drops RDX7675
www.rttnews.com - November 22 at 2:43 AM
BRIEF-Ardelyx Inc says has decided to discontinue development of RDX7675 for treatment of hyperkalemiaBRIEF-Ardelyx Inc says has decided to discontinue development of RDX7675 for treatment of hyperkalemia
www.businessinsider.com - November 21 at 4:36 PM
Ardelyx (ARDX) Updates Development Path for Cardiorenal PipelineArdelyx (ARDX) Updates Development Path for Cardiorenal Pipeline
www.streetinsider.com - November 21 at 4:36 PM
Cytokinetics Shares Plunge on Study Results for ALS Drug -- Biotech MoversCytokinetics Shares Plunge on Study Results for ALS Drug -- Biotech Movers
finance.yahoo.com - November 21 at 4:36 PM
Stock Performance Review on Biotech Industry -- Ardelyx, Bellicum Pharma, Iovance Biotherapeutics, and Inotek PharmaStock Performance Review on Biotech Industry -- Ardelyx, Bellicum Pharma, Iovance Biotherapeutics, and Inotek Pharma
www.bizjournals.com - November 16 at 4:15 PM
Stock Performance Review on Biotech Industry -- Ardelyx, Bellicum Pharma, Iovance Biotherapeutics, and Inotek Pharma - PR Newswire (press release)Stock Performance Review on Biotech Industry -- Ardelyx, Bellicum Pharma, Iovance Biotherapeutics, and Inotek Pharma - PR Newswire (press release)
www.prnewswire.com - November 16 at 11:26 AM
Ardelyx, Inc. (ARDX) Receives Consensus Rating of "Buy" from AnalystsArdelyx, Inc. (ARDX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - November 16 at 9:08 AM
Ardelyx, Inc. (ARDX) Short Interest UpdateArdelyx, Inc. (ARDX) Short Interest Update
www.americanbankingnews.com - November 13 at 2:32 AM
Ardelyx, Inc. (ARDX) Upgraded to "Buy" at Zacks Investment ResearchArdelyx, Inc. (ARDX) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - November 11 at 8:58 PM

SEC Filings

Ardelyx (NASDAQ:ARDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ardelyx (NASDAQ:ARDX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ardelyx (NASDAQ ARDX) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.